Abstract
Although many new and helpful treatments for dry eye disease have been developed, there remains a subset of patients who continue to look for easier or more effective treatments. A consecutive group of 28 moderate to severe dissatisfied dry eye patients in one practice were surveyed after initial exposure to and trial with a novel intranasal neurostimulation technique. Results were overall positive. Seventy-one percent had a favorable impression. Average rating on 1-10 scale was 6.92. Twenty-five percent purchased the device immediately despite no insurance coverage. Of those who did not buy, 100% said they would consider purchase later. Time and experience will show how valuable this new technology is and how it fits in the dry eye armamentarium.
Highlights
Despite many treatment advances in recent years, dry eye disease remains a conundrum for both doctors and patients
FDA approval for True Tear was granted in April, 2017, “to provide a temporary increase in tear production during neurostimulation in adult patients.”
All devicerelated events were mild, including nasal pain, discomfort or burning (10.3%) transient electrical discomfort (5.2%), and nosebleed (5.2%) [1]
Summary
Despite many treatment advances in recent years, dry eye disease remains a conundrum for both doctors and patients. An innovative biotech team in the Silicon Valley (Oculeve) produced a minimally invasive intranasal neurostimulation device for treating dry eye. FDA approval for True Tear was granted in April, 2017, “to provide a temporary increase in tear production during neurostimulation in adult patients.”. Neurostimulation for medical benefit is a concept at least several decades old. For years these techniques have benefited patients with multiple conditions such as chronic pain, post-herpetic neuralgia, complex migraines, and peripheral neuropathy. Patients with Parkinson’s disease [3], intractable epilepsy [4], and even obstructive sleep apnea [5], have benefited from neurostimulation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
